SEC-sourced researchBeta
PMCB
PharmaCyte Biotech, Inc.
Company comparison ↗
Data passport
- CIK
- 0001157075
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Sep 14, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| April 2024 | 0.0000 | Aug 11, 2025 |
| April 2025 | 0.0000 | Aug 11, 2025 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| April 2025 | 0.0000 | 30,656,050.0000 | -2,978,296.0000 | 55,168,353.0000 | 3,277,284.0000 | Aug 11, 2025 |
| April 2024 | 0.0000 | 333,763.0000 | -2,151,457.0000 | 59,903,883.0000 | 20,389,264.0000 | Aug 11, 2025 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $0 | April 2025 | Aug 11, 2025 | 10-K |
| Previous period revenueRevenues | $0 | April 2024 | Aug 11, 2025 | 10-K |
| Net incomeNetIncomeLoss | $30.66M | April 2025 | Aug 11, 2025 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$2.98M | April 2025 | Aug 11, 2025 | 10-K |
| Total assetsAssets | $55.17M | April 2025 | Aug 11, 2025 | 10-K |
| Total liabilitiesLiabilities | $3.28M | April 2025 | Aug 11, 2025 | 10-K |